What causes Spinal Muscular Atrophy?

• SMN1 gene deletion or mutation — the primary genetic cause; reduces production of the SMN protein essential for motor neuron survival.
• SMN2 copy number — acts as a genetic modifier; more copies generally correlate with milder disease and later onset.
• Autosomal recessive inheritance — both parents typically carry one faulty SMN1 copy without symptoms themselves; genetic counseling is recommended for at-risk families.
• Progressive motor neuron loss — the mechanism driving muscle weakness, reduced mobility, and — in severe cases — respiratory compromise.
• Secondary complications — weakened respiratory and swallowing muscles increase infection risk and nutritional challenges, which materially affect long-term outcomes independent of the underlying genetic cause.

Why type matters for treatment discussion

SMA Type 1 (infantile onset), Type 2, Type 3, and Type 4 (adult onset) differ enormously in severity, rate of progression, and which interventions are realistic. A Type 1 infant already on gene therapy is evaluated very differently from an adult with milder Type 3 symptoms — this is why no protocol is proposed at Viezec without first confirming genetic subtype and current treatment status. See Diagnosis for how subtype is confirmed.

Related: Muscular Dystrophy Causes — a different genetic muscle disorder often confused with SMA by families researching muscle-weakness conditions.

What are the symptoms of Spinal Muscular Atrophy?

Symptoms and their severity depend heavily on SMA type and age of onset:

• Muscle weakness in the trunk, arms, or legs — typically proximal (closer to the body) before distal.
• Poor muscle tone (“floppiness”) in infants, or delayed motor milestones such as sitting, crawling, or standing.
• Difficulty with head control in infants with Type 1.
• Weak cry, feeding, or swallowing difficulty in infants — a sign requiring prompt evaluation.
• Respiratory weakness — frequent chest infections, shallow breathing, or visible effort during breathing.
• Tremor in the hands (sometimes seen in later-onset types).
• Muscle twitching (fasciculations), particularly in the tongue.

When to seek immediate evaluation: A child with marked floppiness, weak cry, or feeding/breathing difficulty needs urgent pediatric neurology assessment — early genetic confirmation directly affects eligibility for time-sensitive approved gene therapies, not just supportive options.

How is Spinal Muscular Atrophy diagnosed?

At Viezec, genetic confirmation is a prerequisite — no stem cell evaluation proceeds without it, since candidacy and current treatment status (whether the patient is already on gene therapy) directly shape what, if anything, is appropriate to discuss. If you have existing genetic test results and EMG reports, you can upload them for a free specialist review rather than repeating testing unnecessarily.

Stem Cell Treatment for Spinal Muscular Atrophy in India

Stem cell approaches for SMA are studied as a supportive, investigational addition to standard care — not a substitute for approved gene or disease-modifying therapies. At Viezec, this is delivered by our specialist team at our accredited New Delhi facility, with mesenchymal stem cells (MSCs) selected based on the patient’s genetic confirmation, current treatment status, and overall functional evaluation.

How does it work?

Research into mesenchymal stem cells for SMA has explored several potential mechanisms:

• Motor neuron support — MSCs release neurotrophic factors that may help protect surviving motor neurons, rather than replace those already lost.
• Inflammation modulation — potential to reduce local inflammatory processes affecting neuromuscular junction health.
• Neuromuscular junction support — early research suggests a supportive role in maintaining nerve-to-muscle signal transmission.

Who may be considered?

• Patients with genetically confirmed SMA (Type 1–4), evaluated individually regardless of type.
• Patients already receiving or having completed approved gene/disease-modifying therapy, being evaluated for an adjunct supportive option — not as an alternative to that therapy.
• Patients for whom a full neurological, respiratory, and functional baseline has been completed.

Patients are not offered stem cell therapy as a substitute for currently accessible, approved gene therapies where those are indicated and available — our specialists will say so directly.

What to expect: the treatment process

1. Genetic and functional evaluation — confirmation of SMA subtype, current treatment status, respiratory and motor baseline.
2. Cell sourcing and GMP processing — selection of an appropriate MSC source, processed under controlled laboratory conditions.
3. Targeted administration — delivered via delivery method appropriate to the case (see below).
4. Integrated supportive care — physiotherapy, respiratory, and nutritional planning alongside the cellular therapy.
5. Ongoing monitoring — motor function scales, respiratory assessments, and developmental tracking over 3–12 months.

Most patients require a 5–10 day in-country stay, with remote follow-up continuing for 6–12 months. For international families, see our medical visa process and plan-your-visit guidance.

Stem Cell Delivery Methods for Spinal Muscular Atrophy

Delivery route is selected based on which part of the motor neuron environment needs to be reached:

• Intrathecal delivery — cells introduced into the cerebrospinal fluid space for broader distribution around the spinal cord; the most commonly discussed route for CNS-targeted SMA research.
• Image-guided intraparenchymal delivery — direct placement when more precise targeting is required, performed under neurosurgical guidance.
• Intravenous infusion — used for systemic supportive strategies, typically alongside a targeted route rather than in place of one.

All procedures follow GMP-prepared cell products, strict aseptic technique, and are performed by neurology/neurosurgery teams with continuous monitoring. See our general Stem Cell Delivery Methods page for how these routes compare across other neurological conditions we treat, including ALS/MND and Multiple Sclerosis, where similar CNS-targeted approaches are used.

Improvements & Results

Reported observations from patients and caregivers combining regenerative approaches with multidisciplinary care include changes in the following areas. As with all sections on this page, these are reported outcomes, not guarantees, and vary substantially by SMA type and baseline status.

Motor Function

Physiotherapy and supportive strategies aim to maintain or improve limb strength and functional reach for daily tasks.

Respiratory Stability

Structured monitoring and respiratory interventions aim to improve breathing efficiency and reduce infection-related complications.

Functional Independence

Adaptive equipment, caregiver training, and occupational therapy support safer, more independent daily activities.

Quick FAQ

Does stem cell therapy reverse SMA-related muscle loss?

No — current research focuses on supporting remaining motor neuron function, not regenerating neurons already lost.

How is improvement measured?

Through motor function scales, respiratory assessments, and physiotherapy evaluations at regular intervals — not through self-reported symptoms alone.

Is respiratory improvement guaranteed?

No. Some patients and caregivers report improved breathing efficiency, but this depends heavily on SMA type and stage at the time of evaluation.

Consult Our Specialists

Mechanism of Action: How Stem Cells May Support Nerve and Muscle Health in SMA

• Motor neuron support — MSCs release neurotrophic factors that may help protect surviving motor neurons from further degeneration.
• Muscle fiber support — growth factors may help maintain healthier surrounding muscle tissue.
• Inflammation regulation — MSCs may help moderate inflammatory processes that affect neuromuscular junction function.
• Oxidative stress reduction — some research points to a role in reducing oxidative stress linked to disease progression.

These remain proposed, researched mechanisms rather than established clinical facts. Every treatment at Viezec is delivered under strict clinical oversight — see our Treatment Safety and Safety and Guarantees FAQ pages for more detail.

Our Promise

• No cure claims. Stem cell therapy for SMA is presented as investigational and supportive — never marketed as a cure or a replacement for approved gene therapies.
• Genetic confirmation and current treatment status required first. No protocol is proposed without knowing the patient’s confirmed SMA type and whether they’re already on approved therapy.
• Named, credentialed medical oversight. Every plan is reviewed by a qualified neurology/regenerative medicine specialist.
• Regulatory transparency. Our protocols operate within India’s ICMR guidelines for investigational stem cell use, disclosed clearly on request.
• Accredited facilities. NABH accreditation and NABL accreditation — verifiable through each body’s public registry.
• Written, itemized cost estimates provided after medical evaluation, before any commitment.
• Honest evidence communication. Where evidence is early-stage — as it is for stem cell therapy in SMA — we say so directly and separate it clearly from the stronger evidence base behind approved gene therapies. See Scientific References.

Testimonials

Aarav M. – Delhi, India – February 2020 – ⭐⭐⭐⭐☆
“My son had weak muscles due to SMA. After Viezec’s stem cell therapy, his strength improved, and he can now sit more steadily.”

Olivia P. – New York, USA – July 2020 – ⭐⭐⭐⭐⭐
“Our daughter showed progress in movement after treatment. Viezec’s therapy gave her better control over her legs and renewed hope for us.”

Ahmed R. – Cairo, Egypt – January 2021 – ⭐⭐⭐⭐☆
“SMA had made daily life very challenging. Post stem cell therapy at Viezec, my stamina improved, and I can walk longer distances with support.”

Sophia L. – London, UK – September 2021 – ⭐⭐⭐⭐⭐
“We noticed real changes in our child’s posture and breathing after treatment. Viezec’s doctors were supportive and caring throughout.”

Miguel S. – Madrid, Spain – March 2022 – ⭐⭐⭐⭐☆
“My son regained partial muscle control after Viezec’s therapy. Physiotherapy became more effective, and his quality of life improved.”

Hannah G. – Toronto, Canada – October 2022 – ⭐⭐⭐⭐⭐
“Before therapy, SMA left me weak and dependent. After Viezec’s treatment, I gained more energy and better hand coordination.”

Omar A. – Dubai, UAE – April 2023 – ⭐⭐⭐⭐☆
“Stem cell therapy gave my daughter more independence. Her muscle strength improved, and she can now manage simple tasks alone.”

Chloe W. – Sydney, Australia – November 2023 – ⭐⭐⭐⭐⭐
“After Viezec’s therapy, my son’s mobility improved. He can now stand with support, something we never thought possible before.”

Fatima Z. – Riyadh, Saudi Arabia – February 2024 – ⭐⭐⭐⭐☆
“Our child had difficulty breathing due to SMA. Post-treatment, his breathing became easier, and his energy levels increased.”

Marco B. – Rome, Italy – June 2025 – ⭐⭐⭐⭐⭐
“Stem cell therapy at Viezec improved my stamina and reduced muscle weakness. I feel stronger and more optimistic about my future.”

Treatment Results

Patients receiving stem cell approaches at Viezec, alongside standard SMA care, may report changes in muscle tone, motor control, fatigue levels, and activity tolerance over 6–12 months. Degree of change varies substantially by SMA type, age, and baseline motor/respiratory function — this is not a guaranteed outcome, and stem cell therapy remains investigational for SMA specifically.

Progress is tracked using motor function scales, respiratory assessments, and physiotherapy evaluations rather than self-report alone — see the monitoring approach under Improvements.

Discuss Your Case

Treatment Disclaimer

Ahead of undergoing this process, a patient or caregiver needs to understand that stem cell therapy for SMA is an experimental, investigational approach that might not produce the desired result in every case. At the time of evaluation, treatment may be declined, or the proposed protocol may change based on the patient’s genetic subtype, current treatment status, and overall health condition.

Distinct from stem cell therapy: Approved gene and disease-modifying therapies for SMA (onasemnogene abeparvovec, nusinersen, risdiplam) have separate, well-documented efficacy and safety data from clinical trials and real-world registries. Nothing on this page should be read as extending that evidence base to stem cell approaches, and nothing here is intended to discourage or delay access to approved therapies where indicated.

At Viezec, our aim is to offer the best available technology and safety practices proven internationally. As with any medical treatment, no guarantees or claims of cure are made regarding the extent of response. Results vary from patient to patient, even with similar diagnoses. We do not use embryonic or fetal cells in any treatment.